Investor Studios has published an interview with PolarCool’s CEO, Erik Andersson, where he provides an update on the company’s progress and the ongoing rights issue.
“PolarCool’s focus today is on the launch in the United States and Canada, where we are working intensively to obtain market approval and to find a suitable collaboration partner. These are two markets where we see major opportunities for rapid and expansive growth. In parallel, we continue our efforts in Europe with the goal of increasing sales and becoming cash-flow positive. We are also looking forward to receiving the results from the completed boxing study, where a positive outcome would provide biological evidence for the treatment and also make new additional market segments available.”, says PolarCool’s CEO Erik Andersson.
Watch the full interview here Investor Studios – PolarCool CEO interview
For more information
Erik Andersson – CEO PolarCool AB (publ.)
+46 – 73 860 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ.)
PolarCool AB (publ.) is a Swedish medical technology company focused on developing and marketing products in the sports medicine field. Its primary product, PolarCap®, is designed to reduce the impact of concussion through targeted brain cooling. PolarCool works with professional teams across Europe in rugby, football, and ice hockey and it shares are listed on Spotlight Stock Market.
